Updated May 2026 | There are now 11,526 plaintiffs in the hair relaxer MDL — the fourth-largest active multidistrict litigation in the United States. A 2022 NIH study found that women who used chemical hair straighteners more than four times per year had more than double the uterine cancer risk. L’Oréal, Revlon, and others are defendants. Bellwether trials are scheduled for 2026. If you used Dark & Lovely, ORS, Motions, Optimum, or other chemical relaxers and developed uterine cancer — your legal window is open.
For generations of Black women in America, chemical hair relaxers were not a luxury product. They were a routine — sometimes weekly, sometimes monthly, for decades of life. Dark & Lovely. ORS. Motions. Optimum. Affirm. Products marketed with promises of smooth, manageable hair, with images of confident women, with no warnings about what the chemicals they contained could do inside the body over years of regular use.
In October 2022, the National Institutes of Health published the findings of the Sister Study — one of the largest long-term research projects on women’s health ever conducted. What they found shook the personal care industry: women who used chemical hair straightening products more than four times per year had more than double the risk of developing uterine cancer compared to women who never used these products.
The uterine cancer connection was not an isolated finding. Researchers also found associations between chemical hair relaxer use and elevated rates of ovarian cancer, uterine fibroids, and endometriosis. The mechanism: hair relaxers contain a range of endocrine-disrupting chemicals (EDCs) — formaldehyde, parabens, bisphenol-A (BPA), phthalates, and cyclosiloxanes — that the body absorbs through the scalp, particularly when the chemicals are left on for the extended processing times typical of relaxer applications.
Today, 11,526 women have filed lawsuits against the manufacturers of these products. The federal MDL has become the fourth-largest active multidistrict litigation in the United States. Bellwether trials are approaching. And for the millions of women who used these products for years — and who developed uterine cancer, uterine fibroids, or ovarian cancer — the legal system is finally catching up to the science.
What Is in Chemical Hair Relaxers That Causes Cancer?
Understanding the chemistry explains the lawsuit. Chemical hair relaxers work by breaking down the protein bonds in curly or coily hair through a combination of strong alkalis (lye-based or no-lye formulas) and chemical processing agents. But the active straightening chemicals are not the only concern — they are compounded by a range of additional chemical ingredients that have significant hormonal activity in the human body.
The endocrine-disrupting chemicals (EDCs) at issue:
Formaldehyde and formaldehyde-releasing compounds: Formaldehyde — or chemicals that release formaldehyde during application, including methylene glycol, glyoxal, and glutaraldehyde — is a known carcinogen classified by IARC as a Group 1 human carcinogen. Many chemical hair straighteners use formaldehyde or formaldehyde-releasing agents as part of their formula. When relaxers are applied and heated (as in salon applications with flat irons), formaldehyde vapor is released into the air and absorbed through the scalp.
Parabens: Parabens (methylparaben, propylparaben, butylparaben) are widely used preservatives in hair care products. They have estrogenic activity — meaning they mimic estrogen in the body — and have been detected in breast and endometrial tissue. The endometrium (the lining of the uterus) is highly responsive to estrogen signaling. Excess estrogenic stimulation is a documented risk factor for endometrial cancer.
Phthalates: Phthalates are plasticizer chemicals used as fragrance carriers and texture modifiers. They are potent endocrine disruptors affecting estrogen and androgen pathways. Phthalates are absorbed through the skin and have been linked in multiple studies to elevated rates of reproductive cancers.
Bisphenol-A (BPA): BPA is an estrogenic chemical found in some hair care product formulations and packaging. Like parabens, it has estrogenic activity that can stimulate hormone-sensitive tissue.
Cyclosiloxanes: Silicone-based smoothing agents used in many relaxer formulas. Studies have linked cyclosiloxane exposure to endocrine disruption and reproductive toxicity.
The scalp absorption pathway: The scalp is among the most absorptive surfaces on the human body — its absorption rate for many chemicals is significantly higher than other skin surfaces. Chemical relaxers applied to the scalp, particularly when left on for 20 to 45 minutes during standard relaxer processing, deliver an extended period of chemical contact with the body’s most absorptive surface. Women who relaxed their hair monthly for decades — beginning in childhood in many cases — accumulated significant cumulative chemical exposure through this pathway.
The NIH Study That Changed Everything
The October 2022 NIH Sister Study publication was the scientific catalyst for the litigation. Here is what it found and why it matters:
Study design: The Sister Study enrolled 50,884 women who were sisters of breast cancer patients — a cohort specifically selected to study cancer risk factors. Participants were followed from 2003 to 2009 and provided detailed information about personal care product use. 378 of these women were subsequently diagnosed with uterine cancer.
The finding: After adjusting for confounding factors including age, BMI, race, and reproductive history, the researchers found:
- Women who used hair straightening products (chemical relaxers or other chemical straighteners) in the previous 12 months had a significantly elevated uterine cancer risk
- Women who used these products more than four times per year had a 2.0 to 2.5 times higher risk of developing uterine cancer compared to non-users
- The association remained statistically significant after controlling for race — meaning the elevated risk was present regardless of race, though the products are disproportionately used by Black women
Context on uterine cancer risk: Uterine cancer affects approximately 3% of women over a lifetime under typical exposure conditions. Among frequent hair relaxer users, the NIH data suggests that risk may exceed 4%. For a cancer that is otherwise relatively uncommon, this represents a population-level doubling of risk — exactly the type of elevated risk that drives mass tort litigation.
Subsequent research: Since the 2022 NIH study, additional peer-reviewed research has reinforced the association:
- A 2024 JAMA study found a dose-response relationship between hair relaxer use and endometrial cancer — meaning the more frequently women used these products, the higher their risk
- Research on specific chemical components — particularly the endocrine-disrupting chemicals identified above — has strengthened the biological plausibility of the cancer link
- Laboratory studies have identified cancer-promoting mechanisms for several of the EDCs present in hair relaxers
The MDL — Where the Litigation Stands in May 2026
MDL 3060 — In re: Hair Relaxer Marketing, Sales Practices and Products Liability Litigation Northern District of Illinois | Judge Beth Jantz
As of May 24, 2026: 11,526 plaintiffs — the fourth-largest active MDL in the United States. New cases continue to be filed weekly.
The litigation timeline:
February 2023: Hair relaxer cases consolidated into MDL 3060 in the Northern District of Illinois.
January 8, 2026 — Science Day: Both plaintiffs and defendants presented the scientific and medical evidence linking hair relaxers to uterine cancer to Judge Jantz. Science Days in mass tort litigation are pivotal — they allow the judge to develop an informed understanding of the science before ruling on expert testimony, causation standards, and admissibility. The January 2026 Science Day preceded several key rulings on document production and discovery.
January 2026 — Document Production Orders: Judge Jantz ordered defendants and third parties to produce documents, data, and testimony by January 23, 2026, addressing multiple disputes over evidence sharing and data access.
December 2025 — New York Judge Denies Motion to Dismiss: A New York state court judge denied Namaste Laboratories’ motion to dismiss a hair straightener cancer lawsuit filed by Mayra Garcia (who developed endometrial cancer after years of use), allowing all claims — including design defect and failure to warn — to proceed. This is a meaningful signal: the legal theories underpinning these lawsuits are surviving early defense challenges.
May 2026 — Court Approves New Procedures: The court approved updated case management procedures, with the litigation continuing to move toward the bellwether trial phase.
Bellwether trials: First bellwether trials are scheduled for 2026 — involving only claims with diagnoses of uterine, endometrial, or ovarian cancer. These initial trials will provide the jury response data that shapes settlement negotiations for the thousands of additional claims. No actual jury verdicts have been returned yet — the litigation is in its critical pre-trial phase.
No settlements reached: As of May 2026, no global or individual settlements have been announced in the hair relaxer MDL. The first jury trials will establish the damages template that enables meaningful settlement negotiations. Cases filed now are positioned to benefit from the settlement framework those trials will create.
Who Is Being Sued — The Defendants
The hair relaxer litigation names multiple cosmetic companies that manufactured and sold chemical hair straightening products primarily to Black women and women of color:
L’Oréal USA / SoftSheen-Carson: L’Oréal is the largest defendant in the hair relaxer MDL. Its subsidiary SoftSheen-Carson manufactures some of the most widely used hair relaxer brands in the country:
- Dark & Lovely — arguably the most recognized chemical relaxer brand in the U.S.
- Dark & Lovely Beautiful Beginnings (children’s formula)
- Optimum Care relaxer system
- Soft Sheen Alternatives and related lines
L’Oréal’s global revenue exceeds $40 billion annually. The company has financial capacity to settle this litigation — which matters both for plaintiffs and for the advertisers who will bid heavily to reach women searching for L’Oréal-related legal information.
Revlon: Revlon manufactures several chemical relaxer products, including Realistic Cream Relaxer and related formulations. Revlon filed for Chapter 11 bankruptcy in 2022, which has complicated the litigation trajectory for Revlon-specific claims. The bankruptcy reorganization is relevant to how Revlon-connected claims proceed.
Strength of Nature / Godrej SON Holdings: Manufactures multiple professional and consumer hair relaxer lines including African Pride, Profectiv MegaGrowth, and others. A case filed this week in the N.D. Illinois MDL names Godrej SON Holdings.
Namaste Laboratories: Manufactures ORS (Olive Oil Relaxer System) — widely used across the market. The December 2025 New York ruling specifically allowed claims against Namaste to proceed, defeating the motion to dismiss.
American International Industries (AII): Manufactures TCB Naturals and other relaxer products.
Other named defendants:
- Procter & Gamble (certain hair care formulations)
- Regis Corporation (salon-use products)
- Various salon product distributors
Who Qualifies for a Hair Relaxer Lawsuit?
Core eligibility requirements:
1. Product use: You used chemical hair relaxers or chemical straighteners regularly — typically at least once per year for a minimum of one year, with stronger cases involving frequent use (4+ times per year) over extended periods (5+ years).
Products that qualify: Any chemical hair relaxer or straightener product, not limited to the brand names above. The litigation covers lye-based relaxers, no-lye relaxers, chemical straighteners marketed for natural hair, and professional-use salon relaxer systems. Use can be self-applied at home or applied in a salon.
2. Cancer or qualifying health condition diagnosis:
Tier 1 — Strongest evidence, highest case values:
- Uterine cancer / endometrial cancer — the primary cancer established in the NIH Sister Study
- Ovarian cancer — secondary association with elevated risk
- Fallopian tube cancer
Tier 2 — Reproductive health conditions:
- Uterine fibroids (benign tumors of the uterine muscle) requiring medical treatment or surgery
- Endometriosis requiring surgery
- Hysterectomy required as a result of fibroids or endometrial conditions
Note on fibroids: Uterine fibroids are extremely common among Black women (affecting up to 70% over a lifetime) and their connection to chemical hair relaxer use is supported by research. However, fibroid claims currently face greater scientific scrutiny in the MDL than uterine/endometrial cancer claims. The most valuable claims in the current litigation involve uterine or endometrial cancer diagnoses.
3. Timing: Your cancer diagnosis should have occurred after a period of regular hair relaxer use. The NIH study specifically focused on women who used these products in the 12 months preceding diagnosis, but the biological mechanism — cumulative EDC exposure over years — means that longer-term prior use is also relevant.
4. Statute of limitations: Most states allow 2 to 4 years from diagnosis (or from when you connected your diagnosis to hair relaxer use) to file a product liability claim. The discovery rule — starting the clock when you knew or should have known about the connection — extends the window in many states.
Settlement Value — What These Cases May Be Worth
No settlements have been paid yet. The first bellwether trials will establish the jury award range, which then shapes settlement negotiations for all other plaintiffs. Based on expert projections and comparable mass tort outcomes:
Projected compensation ranges:
| Condition | Severity | Projected Settlement Range |
|---|---|---|
| Uterine/endometrial cancer — Stage I/II, treated | Moderate | $150,000 – $500,000 |
| Uterine/endometrial cancer — Stage III/IV | Serious | $400,000 – $1,000,000+ |
| Uterine cancer requiring hysterectomy | Significant surgical | $200,000 – $700,000 |
| Ovarian cancer — early stage | Moderate | $150,000 – $500,000 |
| Ovarian cancer — advanced | Serious | $400,000 – $1,500,000+ |
| Wrongful death from uterine/ovarian cancer | Wrongful death | $300,000 – $2,000,000+ |
| Uterine fibroids requiring major surgery | Moderate | $50,000 – $200,000 |
What drives higher values:
- Young age at cancer diagnosis (reproductive years, career impact, childcare implications)
- Need for hysterectomy (permanent loss of fertility)
- Advanced cancer stage at diagnosis with evidence of delayed detection
- Long duration of relaxer use and high frequency (4+ times/year for 10+ years)
- Strong documentary evidence of specific product use
- Evidence that specific defendants’ products were used based on dates and receipts
The Racial Health Equity Dimension
This litigation has a dimension absent from most mass torts: the products at issue were marketed specifically and almost exclusively to Black women.
Chemical hair relaxers in their modern form were developed primarily for tightly coiled African American hair textures. They are marketed, advertised, and sold almost entirely to Black women and women of African descent. White women are not the primary demographic for chemical hair straightening products in the United States.
The NIH Sister Study’s uterine cancer finding — that frequent users have more than double the risk — lands disproportionately on Black women because Black women use these products at far higher rates. And Black women already face significantly elevated rates of uterine cancer — diagnosed at younger ages and with worse outcomes than white women, at rates researchers have long attributed partly to environmental exposures.
The lawsuits allege that chemical companies marketed these products to Black women with full awareness of their chemical composition, without warning about the EDC content that their own formulation scientists understood, and without conducting the long-term health studies on their primary consumer base that the products warranted.
L’Oréal — whose Dark & Lovely brand has been marketed to Black women for decades — faces the most direct scrutiny on this dimension. The advertising record in this litigation: images of Black women with smooth hair, messaging about empowerment and beauty, and no warnings about the endocrine-disrupting chemicals in the formula.
The Failure-to-Warn Legal Theory — Why the Lawsuits Are Winning Early Motions
The core legal theory in every hair relaxer lawsuit is failure to warn: the manufacturers knew their products contained endocrine-disrupting chemicals with cancer-associated biological activity, had an obligation to disclose material risks to consumers, and chose not to.
What the lawsuits allege companies knew:
Product safety scientists formulating hair relaxers had access to:
- IARC classifications on formaldehyde (Group 1 carcinogen)
- Research on estrogenic activity of parabens dating to the 1990s
- Phthalate endocrine disruption research
- Internal safety data on ingredient absorption rates through scalp tissue
The December 2025 New York court ruling allowing claims against Namaste to proceed specifically cited allegations that the products “contained endocrine-disrupting chemicals but were marketed as safe” — a direct acknowledgment that the failure-to-warn theory is legally viable.
The design defect theory: Beyond failure to warn, plaintiffs also pursue design defect claims — alleging that safer formulations were available (products without the EDCs, or with reformulated ingredients) and that companies chose the less safe formulation for cost or performance reasons.
How to File a Hair Relaxer Lawsuit in 2026
Step 1 — Document your product use history
Think back: which products did you use? How often? For how many years? Starting from what age? Useful documentation:
- Product containers (many women keep these)
- Hair salon records showing relaxer applications
- Photographs from the period of use
- Receipts (if saved)
- Family member testimony confirming regular use
You don’t need receipts going back 20 years. Your testimony about what you used and how often is itself evidence — strengthened by any physical documentation you can provide.
Step 2 — Gather medical records
Your cancer diagnosis must be documented by your treating physician. Gather:
- Pathology report confirming uterine, endometrial, or ovarian cancer diagnosis
- Surgical records if hysterectomy or oophorectomy was performed
- Oncology treatment records
- Any records documenting hysterectomy for fibroids
Step 3 — Contact a hair relaxer attorney for a free evaluation
Every attorney handling hair relaxer cases works on full contingency — zero upfront cost, no fees unless compensation is recovered. The evaluation is free and takes 15 to 30 minutes. The attorney confirms your case meets current MDL eligibility criteria and advises on whether to file now or wait for bellwether trial outcomes.
Step 4 — File your claim into MDL 3060
Your attorney files a short-form complaint into MDL 3060 in the Northern District of Illinois, incorporating the master complaint by reference and adding your case-specific facts. The filing places you in the litigation before any settlement framework is established.
Statute of Limitations — Don’t Miss Your Window
| State | Product Liability SOL | Notes |
|---|---|---|
| Illinois | 2 years from discovery | MDL located in N.D. Illinois |
| California | 2 years from discovery | Discovery rule extends for latent injuries |
| New York | 3 years | N.Y. state case survived motion to dismiss |
| Texas | 2 years | Strict |
| Florida | 4 years | Product liability rule |
| Georgia | 4 years | |
| North Carolina | 3 years | |
| Ohio | 2 years | |
| Pennsylvania | 2 years | |
| Michigan | 3 years |
The discovery rule advantage: If you were diagnosed with uterine cancer before the 2022 NIH study made the hair relaxer connection widely known, you may be able to argue that the discovery rule starts your clock from 2022 — when you first could have reasonably connected your cancer diagnosis to your hair relaxer use. Consult an attorney about how this rule applies to your specific facts.
Frequently Asked Questions
I used hair relaxers for years but don’t remember the specific brand. Can I still file? Yes. You don’t need to identify the specific brand to file a claim. Your testimony about the type of product used (lye relaxer, no-lye relaxer, texturizer), the frequency of use, and the duration of use establishes the exposure pattern. Product identification can often be confirmed through hair salon records, family testimony, or photographic evidence from the period.
I had a hysterectomy for fibroids — does that qualify? Potentially yes. Uterine fibroids requiring surgery — particularly total hysterectomy — are among the qualifying conditions being evaluated in the hair relaxer litigation. While fibroid claims currently have a lower projected case value than cancer claims, they are part of the litigation and may have compensable value depending on the specifics. Consult an attorney.
I only used relaxers in a salon — can I still file? Yes. Whether you applied relaxers yourself at home or had them applied professionally in a salon, the chemical exposure was the same. Salon applications often involve more extensive exposure due to the total amounts used and the application technique.
I am a hairdresser who applied relaxers to clients for years — do I qualify? Hairdressers and cosmetologists who applied chemical relaxers occupationally — potentially on a daily basis in enclosed salon environments — have been specifically discussed in the MDL as a category of potentially high-exposure plaintiffs. Occupational exposure through handling, applying, and breathing the chemicals released during relaxer processing may support claims distinct from consumer use cases.
The NIH study was about women who used relaxers in the last 12 months. What if I haven’t used them for years? The NIH study methodology looked at 12-month prior use to establish the exposure-to-diagnosis connection. The biological mechanism involves cumulative EDC exposure over years of use. Prior long-term use — even if discontinued years before diagnosis — is relevant and supports a claim. The latency between chemical exposure and cancer development means past use, not current use, is the key exposure period.
Bottom Line: The Science Is Strong, the Trials Are Coming
The hair relaxer litigation reached 11,526 plaintiffs without a single settlement or jury verdict — a reflection of how the litigation process works in large-scale mass torts. The science has been presented to the judge (Science Day, January 2026). Document production is being enforced. Defense motions to dismiss are failing. Bellwether trials are scheduled.
The next phase of this litigation — the 2026 bellwether trials — will be among the most closely watched in the personal care industry. L’Oréal, the world’s largest cosmetics company, will face a jury on whether its decades-long marketing of Dark & Lovely to Black women, with knowledge of the product’s chemical composition, constituted a failure of the duty to warn.
If you used chemical hair relaxers regularly and were diagnosed with uterine cancer, endometrial cancer, or ovarian cancer — contact a hair relaxer attorney today. The consultation is free. The representation is contingency. And the litigation is at a stage where early-filed cases have the strongest positioning for bellwether trial selection and settlement priority.
This article is for informational purposes only and does not constitute legal advice. Statute of limitations, eligibility, and projected compensation vary by jurisdiction and individual facts. Consult a licensed attorney for guidance specific to your situation.
Last updated: May 2026 | Data sourced from MDL 3060 docket data, Lawsuit Information Center MDL tracker, NIH Sister Study (2022), JAMA endometrial cancer study (2024), Sokolove Law MDL updates, Motley Rice litigation updates, and verified court filings from the Northern District of Illinois